Harbour BioMed Appoints New President

Dr. Adam Zong takes on leadership role at global biopharmaceutical company.

Apr. 16, 2026 at 8:28am

Got story updates? Submit your updates here. ›

A photorealistic studio still-life image featuring a sleek, modern glass beaker filled with a vibrant blue liquid, symbolizing the precision and focus of the biopharmaceutical company's scientific endeavors.A striking visual representation of the innovative research and development work at the heart of Harbour BioMed's mission.Cambridge Today

Harbour BioMed, a global biopharmaceutical company focused on developing novel antibody therapeutics, has appointed Dr. Adam Zong as its new President. The company, which has operations in Cambridge, Massachusetts, Rotterdam, Netherlands, and Shanghai, announced the leadership change in a press release.

Why it matters

Harbour BioMed is a prominent player in the biopharmaceutical industry, known for its work in antibody discovery and development. The appointment of a new President signals a shift in the company's leadership and could indicate a strategic direction change or renewed focus on certain therapeutic areas.

The details

As the new President, Dr. Zong will be responsible for overseeing Harbour BioMed's global operations and driving the company's research and development efforts. He brings extensive experience in the biopharmaceutical industry, having previously held leadership roles at other prominent pharmaceutical companies.

  • Harbour BioMed announced the appointment of Dr. Adam Zong as President on April 16, 2026.

The players

Harbour BioMed

A global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics, with operations in Cambridge, Massachusetts, Rotterdam, Netherlands, and Shanghai.

Dr. Adam Zong

The newly appointed President of Harbour BioMed, bringing extensive experience in the biopharmaceutical industry.

Got photos? Submit your photos here. ›

The takeaway

The appointment of Dr. Adam Zong as President of Harbour BioMed signals a shift in the company's leadership and could indicate a strategic direction change or renewed focus on certain therapeutic areas within the biopharmaceutical industry.